Viable Non-Pathogenic Bacteria for Ulcerative Colitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis are often ineffective and come with significant side effects, and a substantial proportion of patients are resistant to standard drug therapy.
Innovation Solution
The use of pharmaceutical compositions comprising viable non-pathogenic bacteria from specific microbial taxa, such as Clostridium cluster XVIII, Ruminococcus, Lachnospiraceae, Roseburia, and Eubacterium hallii, to treat or prevent ulcerative colitis, while excluding bacteria from taxa like Fusobacterium and Sutterella.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard drug therapy is used to treat ulcerative colitis, then treatment effectiveness is limited, but side effects and treatment resistance increase
Solution Approach 1:
The patent introduces probiotic bacteria as intermediary organisms that mediate the treatment of ulcerative colitis. These bacteria colonize the gut and produce anti-inflammatory compounds, acting as a biological mediator between the host and the disease, thereby reducing reliance on drugs with harmful side effects
Solution Approach 2:
The probiotic bacteria perform self-service by colonizing the gut environment and autonomously producing anti-inflammatory substances. The bacteria themselves provide the therapeutic effect through their metabolic activities, eliminating the need for external drug administration and its associated side effects
2Ease of operation
If standard drug therapy is used to treat ulcerative colitis, then treatment can be administered, but a substantial proportion of patients are resistant to therapy
Solution Approach 1:
The patent changes the fundamental parameter of treatment modality from chemical drugs to living probiotic organisms. This parameter change transforms the treatment mechanism from pharmacological intervention to biological colonization, thereby overcoming drug resistance through a completely different therapeutic pathway
3Reliability
If fecal microbiota transplantation is used to treat ulcerative colitis, then treatment effectiveness improves, but treatment complexity and risk increase
Solution Approach 1:
The patent segments the complex fecal microbiota into specific, isolated probiotic bacterial strains. Instead of using entire fecal extracts with unknown compositions, the invention isolates and uses only the beneficial bacterial components, thereby simplifying the treatment while maintaining effectiveness
Solution Approach 2:
The patent extracts the beneficial probiotic bacteria from the complex fecal microbiota environment. By taking out only the therapeutic components (specific probiotic strains) and eliminating the complex matrix of fecal material, the treatment becomes simpler, safer, and more controllable while preserving clinical efficacy
Data Source
AI summary
The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.